Dr. Paul Chang is the Chief Safety Officer at Janssen, the Pharmaceutical Companies of Johnson & Johnson, where he is responsible for all aspects of patient safety and pharmacovigilance. Paul joined J&J in 2006, and has held various leadership positions including the Head of Cardiovascular, Metabolism and Internal Medicine Clinical Development and Head of Cardiovascular & Metabolism Medical Affairs prior to his current role. Paul was VP of CV & Immunology Global Clinical Research at Bristol Myers Squibb and Director of CV Clinical Research at Merck prior to joining J&J. Paul received his BA from Columbia University and MD from Yale University. He completed his Internal Medicine residency at Cornell and CV Diseases fellowship at Yale.